Collaborations in the development and validation of imaging biomarkers.
D. Sullivan
2008-06-01
Journal of Nuclear Medicine
Abstract:and Validation of Imaging Biomarkers S pecific physical and physiologic characteristics must be standardized and controlled in the process of evaluating and validating imaging biomarkers. Expertise is therefore needed from physicists, physicians, ‘‘customers’’ (academic and commercial clinical trial specialists), regulators, and payers. Collaborations among academic, commercial, federal, and professional society groups are essential, but defining these collaborations and forming successful and purposeful coalitions in developing biomarkers can be challenging. Because many of us already have an idea of what academics look for in collaboration, I approached this issue by looking first at the commercial/industry point of view and asking, ‘‘Why collaborate?’’ The business management literature includes several definitions, from fairly specific (‘‘Collaboration occurs when people from different organizations or units within 1 organization produce something [or formulate policy; resolve an issue] together through joint effort, resources, and decision making and share ownership of the final product or service’’) to broader perspectives (‘‘The purpose or goal of collaboration is to work across boundaries to deliver better service, value, and outcomes for customers, stakeholders, and communities’’). These definitions share a focus on final outcomes—an important element to remember in collaborating with companies. The industry sees a number of potential advantages in collaboration, including better use of scarce resources, cost savings, the ability to create something that might not be possible otherwise, a higher-quality and better-integrated product or service, potential for organizational and individual learning from collaborative resources, and, most important, an enhanced ability to achieve targeted outcomes. Collaboration is only worthwhile for a company, however, if it passes a critical test: Does it help the organization better achieve the outcomes (not simply outputs) that it intends to achieve? Most good business leaders would ask, ‘‘If you can do it on your own, why collaborate?’’ A willingness to collaborate requires a significant impetus. One of the most important factors driving collaboration in drug and pharmaceutical development today is the complexity of knowledge, expertise, techniques, and instrumentation required. The development of biomarkers, including imaging biomarkers, is an area in which the challenge of complexity drives collaboration.